Author name: Leonardo Arias

The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

The legislation makes no mention of the financial assistance, setting the subsidies up to lapse in just a few weeks.

The legislation makes no mention of the financial assistance, setting the subsidies up to lapse in just a few weeks.

PBMs are pivoting reimbursement models to protect pharmacies from what they say is an unsustainable status quo.

In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, ⁠CEO of Zymeworks and Josh Smiley, president and COO of Zai Lab, about how renewed confidence is driving biotech entering 2026.

Dealmaking in the sector is poised to increase next year after a lull in 2025, as companies use technology, like artificial intelligence, to attract buyers, according to the report.

Unos científicos han reconstruido por vez primera cómo el cerebelo establece sus conexiones con el resto del cerebro durante las etapas más tempranas de la vida.   Los autores del estudio han conseguido describir con detalle las fases en las que estas conexiones nerviosas …

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.

Medtronic and CMR Surgical got the FDA’s green light this month, while SS Innovations applied for clearance. Catch up on the latest in surgical robotics in this coverage roundup.

The money replaces a small portion of a contract Moderna lost when the Department of Health and Human Services canceled $760 million in backing to develop the vaccine, called mRNA-1018.